Mycenax Biotech (4726) - Total Assets
Based on the latest financial reports, Mycenax Biotech (4726) holds total assets worth NT$3.33 Billion TWD (≈ $104.88 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Mycenax Biotech cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Mycenax Biotech - Total Assets Trend (2017–2024)
This chart illustrates how Mycenax Biotech's total assets have evolved over time, based on quarterly financial data. Check earnings quality score of Mycenax Biotech to evaluate the quality of earnings relative to operating cash generation.
Mycenax Biotech - Asset Composition Analysis
Current Asset Composition (December 2024)
Mycenax Biotech's total assets of NT$3.33 Billion consist of 21.9% current assets and 78.1% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 8.0% |
| Accounts Receivable | NT$99.05 Million | 2.9% |
| Inventory | NT$64.94 Million | 1.9% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Mycenax Biotech's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 4726 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mycenax Biotech's current assets represent 21.9% of total assets in 2024, a decrease from 58.3% in 2017.
- Cash Position: Cash and equivalents constituted 8.0% of total assets in 2024, down from 26.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 2.9% of total assets.
Mycenax Biotech Competitors by Total Assets
Key competitors of Mycenax Biotech based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Mycenax Biotech - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.75 | 1.29 | 1.36 |
| Quick Ratio | 0.65 | 1.17 | 1.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$-275.15 Million | NT$183.73 Million | NT$151.73 Million |
Mycenax Biotech - Advanced Valuation Insights
This section examines the relationship between Mycenax Biotech's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.10 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | -10.7% |
| Total Assets | NT$3.37 Billion |
| Market Capitalization | $162.63 Million USD |
Valuation Analysis
Below Book Valuation: The market values Mycenax Biotech's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Mycenax Biotech's assets decreased by 10.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Mycenax Biotech (2017–2024)
The table below shows the annual total assets of Mycenax Biotech from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$3.37 Billion ≈ $106.12 Million |
-10.66% |
| 2023-12-31 | NT$3.77 Billion ≈ $118.79 Million |
-15.33% |
| 2022-12-31 | NT$4.45 Billion ≈ $140.29 Million |
+41.86% |
| 2021-12-31 | NT$3.14 Billion ≈ $98.90 Million |
+79.11% |
| 2020-12-31 | NT$1.75 Billion ≈ $55.22 Million |
+24.47% |
| 2019-12-31 | NT$1.41 Billion ≈ $44.36 Million |
+25.86% |
| 2018-12-31 | NT$1.12 Billion ≈ $35.25 Million |
-14.78% |
| 2017-12-31 | NT$1.31 Billion ≈ $41.36 Million |
-- |
About Mycenax Biotech
Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company's services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers plasmid DNA, antibody-drug c… Read more